Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | POLA1 | P09884 | 1/20 | 0.57 |
| ▸ | POLD1 | P28340 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13970818 | 1.00 | POLB (0.59) | POLBPOLA1POLD1 | |
| SCHEMBL18589104 | 1.00 | POLB (0.59) | POLBPOLA1POLD1 | |
| SCHEMBL3347131 | 0.98 | POLB (0.61) | POLB | |
| SCHEMBL16716006 | 0.91 | POLB (0.57) | POLBPOLA1POLD1 | |
| SCHEMBL3345587 | 0.91 | TYMS (0.66) | — | |
| SCHEMBL30807962 | 0.91 | POLB (0.49) | POLBPOLA1POLD1 | |
| SCHEMBL14930108 | 0.90 | POLB (0.59) | POLBPOLA1POLD1 | |
| SCHEMBL2515240 | 0.90 | POLB (0.59) | POLBPOLA1POLD1 | |
| SCHEMBL10046513 | 0.90 | POLB (0.59) | POLBPOLA1POLD1 | |
| SCHEMBL8600185 | 0.90 | POLB (0.56) | POLBPOLA1POLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 732 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250210148-A1 | METHOD OF PRODUCING DATA-ENCODED NUCLEIC ACID AND NUCLEIC ACID PRODUCED BY THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-06-26 | — | — | US | claimed |
| US-10799602-B2 | Method for increasing expression of RNA-encoded proteins | CUREVAC AG (DE) | 2020-10-13 | — | — | US | claimed |
| US-10293060-B2 | Method for increasing expression of RNA-encoded proteins | CUREVAC AG (DE) | 2019-05-21 | — | — | US | claimed |
| US-20190100784-A1 | RNA ANALYSIS BY TOTAL HYDROLYSIS | CureVac SE (DE) | 2019-04-04 | — | — | US | claimed |
| EP-3423595-A1 | RNA ANALYSIS BY TOTAL HYDROLYSIS | CureVac AG (DE) | 2019-01-09 | — | — | EP | claimed |
| US-20100292135-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-18 | — | — | US | claimed |
| EP-1874801-A4 | INHIBITORS OF RECA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | UNIV NORTH CAROLINA (US) | 2009-03-25 | — | — | EP | claimed |
| EP-1874801-A2 | INHIBITORS OF RECA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | The University of North Carolina at Chapel Hill (US) | 2008-01-09 | — | — | EP | claimed |
| WO-2006096757-A2 | INHIBITORS OF RECA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-09-14 | — | — | WO | claimed |
| US-20060199768-A1 | Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2006-09-07 | — | — | US | claimed |
| EP-4747380-A1 | MODULATING EXPRESSION OF ALAS1 (5'-AMINOLEVULINATE SYNTHASE 1) GENE | CRISPR Therapeutics AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026103936-A1 | CHEMICALLY MODIFIED CIRCULAR RNA MOLECULE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海元码智药生物技术有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-20260137768-A1 | ZIKA VIRUS VACCINE | CureVac SE (DE) | 2026-05-21 | — | — | US | disclosed |
| US-20260137769-A1 | NUCLEIC ACID MOLECULES AND USES THEREOF | CureVac SE (DE) | 2026-05-21 | — | — | US | disclosed |
| CN-122060818-A | Chemically modified circular RNA molecules, methods of making and uses thereof | 上海元码智药生物技术有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2009048928-A1 | METHODS, COMPOSITIONS AND KITS FOR THE IMPROVED DETECTION OF SMALL RNA MOLECULES | KUTYAVIN IGOR VASSILY (US) | 2009-04-16 | — | — | WO | disclosed |
| EP-1874801-A4 | INHIBITORS OF RECA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | UNIV NORTH CAROLINA (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1874801-A2 | INHIBITORS OF RECA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | The University of North Carolina at Chapel Hill (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006096757-A2 | INHIBITORS OF RECA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199768-A1 | Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199768-A1 | Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens | RECQL, DNA2, WRN | POLB 87/4885POLA1 130/4885POLD1 605/4885 |
| US-20100292135-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | RECQL, DNA2, WRN | POLB 87/4885POLA1 130/4885POLD1 605/4885 |
| US-10293060-B2 | Method for increasing expression of RNA-encoded proteins | STING1, UPF1, CUTA | POLB 273/4885POLA1 291/4885POLD1 655/4885 |
| US-10799602-B2 | Method for increasing expression of RNA-encoded proteins | STING1, UPF1, CUTA | POLB 273/4885POLA1 291/4885POLD1 655/4885 |
| US-20260137768-A1 | ZIKA VIRUS VACCINE | ADAR, RNGTT, UPF1 | POLB 1949/4885POLA1 2852/4885POLD1 3101/4885 |
| US-20260137769-A1 | NUCLEIC ACID MOLECULES AND USES THEREOF | RNMT, RNGTT, NSUN3 | POLB 733/4885POLA1 749/4885POLD1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.